ストックスクリーナーアプリを入手
114.13
0.31%
0.00
前日終値:
$114.13
開ける：
$114.13
24時間の取引高:
737.07K
Relative Volume:
0.46
時価総額：
$23.16B
収益：
$5.36B
当期純損益:
$1.43B
株価収益率:
16.14
EPS:
7.0718
ネットキャッシュフロー:
$1.42B
1週間 パフォーマンス:
-7.07%
1か月 パフォーマンス:
-9.68%
6か月 パフォーマンス:
+20.69%
1年 パフォーマンス:
+31.25%
1日の値動き範囲:
$111.67
$114.97
1週間の範囲:
$111.67
$124.23
52週間の値動き範囲:
$82.81
$132.60
Incyte Corp Stock (INCY) Company Profile
Compare INCY vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
114.23 | 25.11B | 5.36B | 1.43B | 1.42B | 7.0718 |
VRTX
Vertex Pharmaceuticals Inc
|
503.29 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
736.94 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
190.66 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
935.68 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | ダウングレード | Jefferies | Buy → Hold |
| 2026-02-05 | 開始されました | H.C. Wainwright | Buy |
| 2026-01-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-12-08 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-11-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-10-08 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | 開始されました | Barclays | Overweight |
| 2025-06-16 | アップグレード | Stifel | Hold → Buy |
| 2025-03-18 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-03-18 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | 開始されました | UBS | Neutral |
| 2024-10-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2024-10-01 | 開始されました | Wolfe Research | Outperform |
| 2024-09-18 | ダウングレード | Truist | Buy → Hold |
| 2024-07-02 | ダウングレード | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | 開始されました | Deutsche Bank | Hold |
| 2024-04-23 | 開始されました | Cantor Fitzgerald | Neutral |
| 2024-02-23 | 開始されました | Jefferies | Buy |
| 2024-02-14 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-11-21 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-25 | 開始されました | Citigroup | Buy |
| 2023-05-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-04-10 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | アップグレード | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | 開始されました | Piper Sandler | Overweight |
| 2022-08-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-08-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-07-28 | 開始されました | Wells Fargo | Equal Weight |
| 2022-02-09 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-07-20 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-02-10 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | 開始されました | Truist | Buy |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-06-16 | 開始されました | The Benchmark Company | Hold |
| 2020-05-06 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-29 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | 再開されました | William Blair | Outperform |
| 2020-03-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | 再開されました | BofA/Merrill | Neutral |
| 2020-01-03 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2020-01-03 | ダウングレード | Mizuho | Buy → Neutral |
| 2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-10-03 | 開始されました | Mizuho | Buy |
| 2019-09-12 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-09-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-09-05 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-05-21 | 開始されました | Credit Suisse | Neutral |
| 2019-05-03 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2019-04-11 | 開始されました | Stifel | Hold |
| 2019-04-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | アップグレード | William Blair | Mkt Perform → Outperform |
すべてを表示
Incyte Corp (INCY) 最新ニュース
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment - Yahoo Finance
INCY Maintained by Wells Fargo -- Price Target Raised to $128 - GuruFocus
Wells Fargo Adjusts Price Target on Incyte to $128 From $116, Keeps Equalweight Rating - marketscreener.com
Incyte Corporation (INCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
INCY or TECH: Which Is the Better Value Stock Right Now? - Zacks Investment Research
Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup - ChartMill
Incyte patents new VRK1 inhibitors - BioWorld News
Incyte Corp Lobbyists, 2019 - OpenSecrets
INCY Maintained by JP Morgan -- Price Target Raised to $123.00 - GuruFocus
INCY Maintained by HC Wainwright & Co. -- Price Target Raised to $152 - GuruFocus
H.C. Wainwright raises Incyte stock price target on Atebrioz approval By Investing.com - Investing.com Nigeria
A legal chief with more than 25 years in pharma and biotech joins MiniMed. - Stock Titan
Mirum Pharmaceuticals and Incyte Compete Regeneron with Abnormal Bone Formation Treatment - Yahoo Finance
Incyte takes FDA approval for Atebrioz as first oral ALK2i for fibrodysplasia ossificans progressiva - AllSci
JPMorgan Adjusts Price Target on Incyte to $123 From $120, Keeps Neutral Rating - marketscreener.com
Incyte Corporation (INCY) Stock Price Today: $123.89 - Pluang
Incyte Corp Lobbyists, 2025 - OpenSecrets
About 300 people in the U.S. have a disease that causes bone to form in soft tissues. FDA approves a treatment. - Stock Titan
Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP patients 12 and older - Mugglehead Investment Magazine
INCYTE CORP (INCY) Stock Chart - ChartMill
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva - Yahoo Finance
Incyte Stock Price Forecast. Should You Buy INCY? - StockInvest.us
FDA Approves Atebrioz for Rare Bone Disorder, Boosting Incyte Co - GuruFocus
Form 4 Incyte Corporation For: 25 September By Investing.com - Investing.com Canada
Form 4 Incyte Corporation For: 25 September - Investing.com India
Bay Area company readies for decision on drug to treat alarming 'stone man' syndrome - The Business Journals
Incyte (INCY) withheld shares from its strategy chief for taxes at a reported $126.93 per share. - Stock Titan
Incyte (INCY) Stock Could Be 34% Above Fair Value After EADV Data - Yahoo Finance
Incyte (INCY) Heads To EADV With New Skin Disease Trial Data - Yahoo Finance
Analysts Offer Insights on NA Companies: Incyte (INCY) and Coherent Corp (COHR) - theglobeandmail.com
How Is Incyte’s Stock Performance Compared to Other Biotech Stocks? - Barchart.com
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Incyte Corporation (INCY) latest stock news and headlines - Yahoo Finance UK
Incyte's Colorectal Cancer Program Remains Risky, Long-Term, RBC Says - marketscreener.com
INCY Reiterated by RBC Capital -- Price Target Maintained at $10 - gurufocus.com
Incyte to present inflammation and autoimmunity data at EADV - Investing.com
Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte’s Inflammation and Autoimmunity Portfolio - Business Wire
INCY Looks 18.6% Overvalued on GF Value™ as of September 2026 - GuruFocus
Incyte Expands Skin Diseases Treatment Partnership in Australia - marketscreener.com
Incyte stock heads into the open after a 1.8% pullback - AD HOC NEWS
Specialised Therapeutics expands Incyte partnership to Australia - Investing.com
More than 1 million patients have used this skin cream. Partners plan to bring it to Australia. - Stock Titan
Incyte stock gains institutional backing as Bank of America boosts position - AD HOC NEWS
Specialised Therapeutics Expands Partnership with Incyte to Include Ruxolitinib Cream (Opzelura®) in Australia - Yahoo Finance
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target - Yahoo Finance
What Is Incyte Corporation (NASDAQ:INCY) Signaling Through Its Pipeline? - Kalkine Media
Incyte stock gains as investors eye September FDA decision and pipeline catalysts - AD HOC NEWS
Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum - ChartMill
MIRM, INCY Stocks In Focus — Will A September 26 FDA Ruling Reward This Week’s Gains? - Stocktwits
Incyte stock heads into the open after a 2.5% gain - AD HOC NEWS
Incyte Corp (INCY) 財務データ
収益
当期純利益
現金流量
EPS
Incyte Corp (INCY) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| CAGNONI PABLO J | President, Global Head of R&D |
Sep 15 '26 |
Sale |
120.49 |
23,218 |
2,797,629 |
183,200 |
0.09%
0.69%
大文字化:
|
ボリューム (24 時間):